RE:earningsI'm telling yea its going to be a net income. Not because of operations but because of non-operating income.
EPS .50+ and that's not including rev from biological assets. If you want a clear visualization of what happened in the quarter. The cash flow statement is the way. It removes all the clutter that occured from unrealized gains/losses, non-cash items etc.
Also.....
july-sept
Rev: $52.50m
COGS: ($24.28m)
Operating: ($60.96m) removed non-cash items and added 15% from june 30 amount
Working Capital: ($125m), a/r,ba,inv,prepaid budget
Total= ($157.74m)
oct-dec
Rev: $125m
COGS: ($77.62m)
Operating: ($70.11m) removed non-cash items and added 15%
Working Capital: ($125m)
Total: ($117.48m)
Operating: $275.22m
Investing: $300m
Financing: $600m
Assets: 6176.78m
Liabilities: (310m)
s/o: 350m
$5866.78m/350m= 16.76 book value
@5x = $83.81
The figures by the year end will not be the same as the ones stated above. However, as long as the book value and share price is above 16.76 and $83.81 respectively, I would be satisfied with the result.
Although, the question of whether it was because of fundamentals or other factors will be up for debate.